Welcome - Register - Login - Help/FAQ - 0 items

Search Enter keywords, a title or a report id number below. In All Categories --------------------- Telecom & Computing Business & Finance Mfg & Construction Pharma & Healthcare Consumer & Retail Gov & Public Sector Energy & Transport Country Reports Company Reports --------------------- Transcripts Advanced      Select a currency for use throughout the site Australia Dollars Canada Dollars Euro Japan Yen Sweden Kroner Switzerland Francs UK Pounds US Dollars Search Results Your Search for 'Target Product Profiles : Physician Insights on Key Attributes - Colon Cancer (Stage III)' returned 7 results - Page 1 of 1  FEATURED RESULTS Cancer Diagnostic Testing World Markets Drug Delivery in Cancer - Technologies, Markets and Companies Antibody Drug Target Atlas in Oncology Lung Cancer, 3rd Edition DNA Repair in Cancer Therapy. Molecular Targets and Clinical...   Sort by    Date Published ASC Date Published DESC Report Price ASC Report Price DESC Rank ASC Rank DESC   Sorted by Rank Top-Bottom Stakeholder Insight: Gastric Cancer   Datamonitor, Sep 2010, Pages: 204 neoadjuvant and adjuvant therapy Resectable Stage II gastric cancer Treatment options Neoadjuvant therapy alone Adjuvant therapy alone Neoadjuvant and adjuvant therapy together Resectable Stage III Cancer Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2017   GlobalData, April 2011, Pages: 108 of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Cancer Pain Therapeutics sector. This report is built using data and information Ovarian Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017   GlobalData, Dec 2010, Pages: 55 and Unmet Need 3.6 Key Takeaway 4 Ovarian Cancer Therapeutics – Competitive Assessment 4.1 Overview 4.2 Strategic Competitor Assessment 4.3 Product Profile for the Major Marketed Products in Ovarian Commercial Insight: Opioids in Australia   Datamonitor, May 2010, Pages: 111 ; QRxPharma) - drug profile in Australia, 2010 Table 27: Phase III trial summary of MoxDuo IR (oxycodone/morphine; QRxPharma) Table 28: Key fentanyl reformulations in late-stage R&D pipeline Stakeholder Insight: Chronic Leukemias - Is there Room left for Improvement?   Datamonitor, Nov 2008, Pages: 362 : LATE-PHASE PIPELINE OVERVIEW 164 Products in Phase III development for CLL 164 Genasense (Oblimersen; Genta) 164 Drug overview 164 Key historical events 165 Datamonitor comments 167 Approval of Genasense Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers   Datamonitor, Dec 2010, Pages: 416 , 2010 Table 28: Victoza franchise (Novo Nordisk) - drug profile, 2010 Table 29: Key products in late-stage R&D glucagon-like peptide-1 (GLP-1) agonists pipeline for diabetes, 2010 Table 30: Forecast Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitors bring added benefits to diabetes therapy.   Datamonitor, Dec 2010, Pages: 416 antidiabetics Target product profile versus current level of attainment 4. R&D Approach Key findings Clinical trial design in non-insulin antidiabetics Efficacy Control of average blood glucose levels Results:  First -   Prev -   1 -   Next -   Last

		For enquiries please call us on:   +353-1-415-1241 (GMT Office Hours)   1-800-526-8630 (US/Canada Toll Free)   1-917-300-0470 (EST Office Hours)

All rights reserved. © Copyright 2012 Research and Markets1    Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network